TWF1 and Parkinson disease: CVN417,a novel selective antagonist at this receptor subtype, attenuatesmotor dysfunction in a Parkinson’s disease-relevant animalmodel, suggesting, for this pathology, a therapeutic strategy thatcould greatly profit from the restricted localization of α6*nicotinic receptors in the brain.